Urodynamix Technologies Ltd. (TSX-V:URO) announced that it has entered into an agreement with Pfizer Inc. to collaborate on a series of promotional programs to increase awareness of UroNIRS(TM) Bladder Monitor technology among urologists and medical professionals.
The program will be delivered to medical professionals in cities across the United States commencing in November 2008 and will feature Urodynamix's UroNIRS technology - a new, non-invasive medical device that uses near infrared spectroscopy for diagnosis of LUTS, a major health concern related to BPH and prostate disease. Experts will discuss the current and future applications of UroNIRS technology for the diagnosis of urologic conditions including LUTS, BPH and erectile dysfunction (ED).
This program will be coordinated through Pfizer's Urology sales force.
"This exciting program allows us to collaborate with Pfizer and our leading distribution partners to deliver the message about the features and benefits of UroNIRS and future applications of our technology," said Barry Allen, President and CEO of Urodynamix.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.
About Pfizer Inc.
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. For more information visit pfizer
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Urodynamix Technologies Ltd.